Minerva Neurosciences Inc (NERV)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $114.62M
Last updated: Nov 17, 2026 at 4:10 PM ET
Minerva Neurosciences Inc (NERV) Stock Chart
Minerva Neurosciences (NERV) has a latest price of $2.16 on Nov 17, 2026, 75.5% below its 52-week high of $8.80. Its price fell 47.4% over the past 12 months. The month-end price fell 97.4% over the 10 years through Oct 2026, a compound annual decline of 30.6%.
Price Chart
From Oct 2016 to Oct 2026, its highest month-end close was $103.20 in Nov 2016 and its lowest $1.54 in May 2025, adjusted for splits.
Month-end closes, adjusted for splits. Dividends are not included.
Chart NERV with Advanced Charting
Daily candlesticks, valuation multiples, side-by-side comparisons and drawings for NERV.
Free with a GNG account. No credit card.
Price Performance
Over the past 3 months the price fell 54.9%, and over 6 months it fell 50.5%. The month-end price fell 51.9% over the 3 years through Oct 2026, a compound annual decline of 21.6%.
| Period | Change |
|---|---|
| 1 month | -6.9% |
| 3 months | -54.9% |
| 6 months | -50.5% |
| 12 months | -47.4% |
| 12 months, with dividends | -47.4% |
| Period | Change | Per year |
|---|---|---|
| 3 years | -51.9% | -21.6% |
| 5 years | -79.3% | -27.0% |
| 10 years | -97.4% | -30.6% |
Price by Year
Its best calendar year was 2023, when the price rose 286.8%, and its weakest was 2022, when it fell 75.2%.
| Year | Close | Change |
|---|---|---|
| 2026 through Oct 2026 | $2.32 | -42.3% |
| 2025 | $4.02 | +81.0% |
| 2024 | $2.22 | -63.9% |
| 2023 | $6.15 | +286.8% |
| 2022 | $1.59 | -75.2% |
| 2021 | $6.41 | -65.8% |
| 2020 | $18.72 | -67.1% |
| 2019 | $56.88 | +5.5% |
| 2018 | $53.92 | +11.4% |
| 2017 | $48.40 | -48.5% |
Trading Range
The price is 26.1% below its 50-day average of $2.92 and 54.9% below its 200-day average of $4.79.
| Measure | Value | Price vs |
|---|---|---|
| Latest price (Nov 17, 2026) | $2.16 | |
| 52-week high | $8.80 | -75.5% |
| 52-week low | $1.96 | +10.2% |
| 50-day average | $2.92 | -26.1% |
| 200-day average | $4.79 | -54.9% |
Price Risk
Over 3 years, its largest fall from a peak was 89.3%.
| Measure | Value |
|---|---|
| 1-year beta | 1.70 |
| Largest fall, 1 year | -73.2% |
| Largest fall, 3 years | -89.3% |
Advanced Charting Features
Advanced Charting is free with a GNG account, and signed-in members get it in place of the price chart above.
- Valuation multiples. Daily P/E, price to sales, cash flow and book value, PEG and PEGY, drawn behind the price wherever the company's data supports them.
- Price charts and drawings. Candlestick, OHLC, line and area charts with volume and earnings, dividend and split markers, plus trend lines, levels and notes kept in your account.
- Side-by-side compare. Two stocks next to each other on one metric and time span, each chart with its own price scale.
- Projections and saved views. Pick a start and an end point to see the price return, dividends and total return between them, and save views to open later.
Frequently Asked Questions About NERV
What is NERV's 1-year price change?
Minerva Neurosciences's price fell 47.4% over the past 12 months. With dividends included, the 12-month total return was -47.4%.
What is NERV's 5-year price change?
Minerva Neurosciences's month-end price fell 79.3% over the 5 years through Oct 2026, a compound annual decline of 27.0%. These figures leave out dividends.
What is NERV's 52-week high and low?
Minerva Neurosciences's 52-week high is $8.80 and its 52-week low is $1.96. Its latest price of $2.16 on Nov 17, 2026 is 75.5% below the high.
What is NERV's beta?
Minerva Neurosciences's 1-year beta against the S&P 500 is 1.70, so its price has moved more than the market over the past year. Its largest fall from a peak over the past year was 73.2%.
Is the NERV chart free?
Yes. Advanced Charting for NERV is free with a GNG account, and no credit card is needed. It adds daily candlestick and line charts with volume, valuation multiples, side-by-side comparisons, drawings and saved views.
NERV pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Competitors